Research programme: vanilloid receptor antagonists - Ligand/Merck

Drug Profile

Research programme: vanilloid receptor antagonists - Ligand/Merck

Alternative Names: NGD 8695; NRGN-16

Latest Information Update: 06 Apr 2010

Price : $50

At a glance

  • Originator Merck & Co; Neurogen Corporation
  • Class Pyridazines; Small molecules
  • Mechanism of Action TRPV cation channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Preclinical Pain
  • No development reported Urinary incontinence

Most Recent Events

  • 23 Dec 2009 Preclinical development is ongoing in USA
  • 08 Dec 2003 Neurogen and Merck & Co. have formed a research collaboration and combined their vanilloid receptor antagonist programmes
  • 03 Oct 2001 Preclinical development for Pain in USA (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top